Features of the course of pregnancy in women with polycystic ovary syndrome

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Polycystic ovary syndrome is one of the most common pathologies in the practice of an obstetrician-gynecologist. Overcoming infertility characteristic of this syndrome is an important problem of endocrinology, gynecology, and reproductive medicine. Innovative therapeutic and surgical methods of treatment can correct hormonal and metabolic disorders, induce ovulation and achieve a long-awaited pregnancy. Early gestation periods in patients with polycystic ovary syndrome often occur with miscarriage, and the risks of developing gestational diabetes mellitus, cervical insufficiency, gestational arterial hypertension, preeclampsia, and placental insufficiency increase. We have analyzed modern ideas about the effect of various pathogenetic links of polycystic ovary syndrome on the course of pregnancy.


Full Text

Restricted Access

About the authors

Igor P. Nikolayenkov

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Author for correspondence.
Email: Nikolaenkov_igor@mail.ru
ORCID iD: 0000-0003-2780-0887

Russian Federation, Saint Petersburg

MD, PhD. The Labor and Delivery Department

Tatyana U. Kuzminykh

Saint Petersburg State University

Email: 9260@mail.ru
Scopus Author ID: 56719818800
ResearcherId: U-8950-2017

Russian Federation, Saint Petersburg

MD, PhD, DSci (Medicine), Associate Professor. The Department of Obstetrics, Gynecology, and Reproductive Sciences, the Faculty of Medicine

Marina A. Tarasova

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: tarasova@ott.ru

Russian Federation, Saint Petersburg

MD, PhD, DSci (Medicine), Professor, Honored Scientist of the Russian Federation. The Educational Department, the Department of Endocrinology of Reproduction

Darya S. Seryogina

The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott

Email: dunyashadasha00@gmail.com

Russian Federation, Saint Petersburg

MD, Post-Graduate Student. The Labor and Delivery Department

References

  1. Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-2438. https://doi.org/10.1210/jcem.85.7.6682.
  2. Azziz R, Adashi EY. Stein and Leventhal: 80 years on. Am J Obstet Gynecol. 2016;214(2):247.e1-247.e11. https://doi.org/10.1016/j.ajog.2015.12.013.
  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. https://doi.org/ 10.1016/j.fertnstert.2003.10.004.
  4. Николаенков И.П., Потин В.В., Тарасова М.А., и др. Активность овариальной ароматазы у больных синдромом поликистозных яичников // Журнал акушерства и женских болезней. − 2014. − Т. 63. – № 1. − С. 10–16. [Nikolayenkov IP, Potin VV, Tarasova MA, et al. Ovarian aromatase activity in polycystic ovarian syndrome. Journal of obstetrics and women’s diseases. 2014;63(1):10-16. (In Russ.)]
  5. Самойлович Я.А., Потин В.В., Тарасова М.А., и др. Дефицит овариальной ароматазы как причина нормогонадотропной ановуляции // Российский вестник акушера-гинеколога. − 2015. − Т. 15. − № 2. − С. 25–30. [Samoilovich YaA, Potin VV, Tarasova MA, et al. Ovarian aromatase deficiency as a cause of normogonadotropic anovulation. Rossiyskiy vestnik akushera-ginekologa. 2015;15(2):15-30. (In Russ.)]. https://doi.org/10.17116/rosakush201515225-30.
  6. Николаенков И.П., Потин В.В., Тарасова М.А. Антимюллеров гормон и синдром поликистозных яичников // Журнал акушерства и женских болезней. − 2013. − Т. 62. − № 6. − С. 55–61. [Nikolaenkov IP, Potin VV, Tarasova MA. Anti-Mullerian hormone and polycystic ovary syndrome. Journal of obstetrics and women’s diseases. 2013;62(6):55-61. (In Russ.)]
  7. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. – 3-е изд. – М.: МИА, 2005. – 632 с. [Smetnik VP, Tumilovich LG. Neoperativnaya ginekologiya: rukovodstvo dlya vrachey. 3rd ed. Moscow: MIA; 2005. 632 p. (In Russ.)]
  8. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-2749. https://doi.org/10.1210/jc.2003-032046.
  9. Чернуха Г.Е., Петрова Н.В., Валуева Л.Г., и др. Особенности липидного спектра крови у больных с синдромом поликистозных яичников // Проблемы репродукции. − 2003. − Т. 9. − № 1. − С. 34–39. [Chernukha GE, Petrova NV, Valueva LG, et al. Osobennosti lipidnogo spektra krovi u bol’nykh s sindromom polikistoznykh yaichnikov. Problemy reproduktsii. 2003;9(1):34-39. (In Russ.)]
  10. Макарищев А.Я. Клиническое значение сосудистого эндотелиального фактора роста при синдроме поликистозных яичников // АГ-ИНФО (Журнал Российской ассоциации акушеров-гинекологов). − 2009. − № 4. − C. 12–18. [Makarishсhev AYa. Klinicheskoe znachenie sosudistogo endotelial`nogo faktora rosta pri sindrome polikistoznykh yaichnikov. AG-INFO (Zhurnal Rossiyskoy assotsiatsii akusherov-ginekologov). 2009;(4):12-18. (In Russ.)]
  11. Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24. https://doi.org/10.1093/humrep/der396.
  12. Palomba S, Falbo A, Russo T, et al. Pregnancy in women with polycystic ovary syndrome: The effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril. 2010;94(5):1805-1811. https://doi.org/ 10.1016/j.fertnstert.2009.10.043.
  13. Журавлева Ю.А., Зильбер М.Ю. Особенности течения беременности и оценка перинатальных исходов у беременных с синдромом поликистозных яичников в зависимости от методов лечения бесплодия // Уральский медицинский журнал. − 2010. − № 3. − С. 33–37. [Zhuravleva YuA, Zilber MU. Evaluation of prenatal outcomes in women with polycystic ovary syndrome depending on a method of treatment of infertility. Ural`skiy meditsinskiy zhurnal. 2010;(3):33-37. (In Russ.)]
  14. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-129. https://doi.org/10.1056/NEJMoa1313517.
  15. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132(12): 989-993. https://doi.org/10.7326/0003-4819-132-12-20000 6200-00010.
  16. Николаенков И.П. Антимюллеров гормон в патогенезе синдрома поликистозных яичников: автореф. дис. ... канд. мед. наук. – СПб., 2014. – 24 c. [Nikolaenkov IP. Antimyullerov gormon v patogeneze sindroma polikistoznykh yaichnikov. [dissertation] Saint Petersburg; 2014. 24 p. (In Russ.)]
  17. Сидельникова В.М. Привычная потеря беременности. – М., 2002. – 303 c. [Sidel`nikova VM. Privychnaya poterya beremennosti. Moscow; 2002. 303 p. (In Russ.)]
  18. Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009;(4):CD002249. https://doi.org/ 10.1002/14651858.CD002249.pub4.
  19. Okun N, Sierra S; Genetics Committee; Special Contributors. Pregnancy outcomes after assisted human reproduction. J Obstet Gynaecol Can. 2014;36(1):64-83. https://doi.org/10.1016/S1701-2163(15)30685-X.
  20. Løvvik TS, Wikström AK, Neovius M, et al. Pregnancy and perinatal outcomes in women with polycystic ovary syndrome and twin births: A population-based cohort study. BJOG. 2015;122(10):1295-1302. https://doi.org/ 10.1111/1471-0528.13339.
  21. Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: A meta-analysis of the observational studies. Clin Endocrinol (Oxf). 2013;78(3):438-446. https://doi.org/10.1111/j.1365-2265.2012.04490.x.
  22. Moran LJ, Cameron JD, Strauss BJ, Teede HJ. Vascular function in the diagnostic categories of polycystic ovary syndrome. Hum Reprod. 2011;26(8):2192-2199. https://doi.org/10.1093/humrep/der159.
  23. Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care. 2010;33(2):246-251. https://doi.org/10.2337/dc09-1516.
  24. Fliegner D, Schubert C, Penkalla A, et al. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol. 2010;298(6):R1597-R1606. https://doi.org/ 10.1152/ajpregu.00825.2009.
  25. Zhu D, Hadoke PW, Wu J, et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. Sci Rep. 2016;6:24807. https://doi.org/10.1038/srep24807.
  26. Айламазян Э.К., Мозговая Е.В. Гестоз: теория и практика. – М., 2008. – 271 c. [Aylamazyan EK, Mozgovaya EV. Gestoz: teoriya i praktika. Moscow; 2008. 271 p. (In Russ.)]
  27. Сидорова И.С., Галинова И.Л. Эндотелиальная дисфункция в развитии гестоза // Вопросы гинекологии, акушерства и перинатологии. − 2006. − Т. 5. − № 1. − С. 75–81. [Sidorova IS, Galinova IL. Endothelial dysfunction in the development of gestosis. Voprosy ginekologii, akusherstva i perinatologii. 2006;5(1):75-81. (In Russ.)]
  28. Acromite MT, Mantzoros CS, Leach RE, et al. Androgens in preeclampsia. Am J Obstet Gynecol. 1999;180(1 Pt 1):60-63. https://doi.org/10.1016/s0002-9378(99)70150-x.
  29. Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;76(1):119-125. https://doi.org/10.1111/j.1365-2265.2011.04171.x.
  30. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800. https://doi.org/10.1210/edrv.18.6.0318.
  31. Мишарина Е.В., Бородина В.Л., Главнова О.Б., и др. Инсулинорезистентность и гиперандрогенемия // Журнал акушерства и женских болезней. − 2016. − Т. 65. − № 1. − С. 75–86. [Misharina EV, Borodina VL, Glavnova OB. Insulin resistance and hyperinsulinemia. Journal of obstetrics and women’s diseases. 2016;65(1):75-86. (In Russ.)]. https://doi.org/10.17816/JOWD65175-86.
  32. Elias I, Franckhauser S, Ferré T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes. 2012;61(7):1801-1813. https://doi.org/10.2337/db11-0832.
  33. Lee IT, Chiu YF, Hwu CM, et al. Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc Diabetol. 2012;11:43. https://doi.org/10.1186/1475-2840-11-43.
  34. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1): 5-12. https://doi.org/10.1007/s11154-012-9229-1.
  35. Maliqueo M, Echiburú B, Crisosto N. Sex steroids modulate uterine-placental vasculature: Implications for obstetrics and neonatal outcomes. Front Physiol. 2016;7:152. https://doi.org/10.3389/fphys.2016.00152.
  36. McClamrock HD, Adashi EY. Gestational hyperandrogenism. Fertil Steril. 1992;57(2):257-274. https://doi.org/10.1016/s0015-0282(16)54828-6.
  37. Nestler JE. Regulation of the aromatase activity of human placental cytotrophoblasts by insulin, insulin-like growth factor-I, and -II. J Steroid Biochem Mol Biol. 1993;44(4-6): 449-457. https://doi.org/10.1016/0960-0760(93)90249-v.
  38. Nestler JE. Insulin and insulin-like growth factor-I stimulate the 3 beta-hydroxysteroid dehydrogenase activity of human placental cytotrophoblasts. Endocrinology. 1989;125(4):2127-2133. https://doi.org/10.1210/endo-125- 4-2127.
  39. Kanasaki M, Srivastava SP, Yang F, et al. Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice. Sci Rep. 2017;7(1):7927. https://doi.org/10.1038/s41598-017-08513-w.
  40. Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008;453(7198):1117-1121. https://doi.org/10.1038/nature06951.
  41. Ngai I, Govindappagari Sh, Neto N, et al. Outcome of pregnancy when gestational diabetes mellitus is diagnosed before or after 24 weeks of gestation. Obstet Gynecol. 2014;123(Suppl 1):162S-163S. https://doi.org/ 10.1097/01.aog.0000447165.22404.99.
  42. Amin M, Suksomboon N, Poolsup N, Malik O. Comparison of glyburide with metformin in treating gestational diabetes mellitus: A systematic review and meta-analysis. Clin Drug Investig. 2015;35(6):343-351. https://doi.org/ 10.1007/s40261-015-0289-3.
  43. Haakova L, Cibula D, Rezabek K, et al. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003;18(7):1438-1441. https://doi.org/10.1093/humrep/deg289.
  44. Koster MP, de Wilde MA, Veltman-Verhulst SM, et al. Placental characteristics in women with polycystic ovary syndrome. Hum Reprod. 2015;30(12):2829-2837. https://doi.org/10.1093/humrep/dev265.
  45. Palomba S, Falbo A, Chiossi G, et al. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: A prospective controlled clinical study. J Clin Endocrinol Metab. 2014;99(8):2942-2951. https://doi.org/10.1210/jc.2014-1214.
  46. Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: A randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448-E455. https://doi.org/10.1210/jc.2010-0853.
  47. Zhao J, Liu X, Zhang W. The effect of metformin therapy for preventing gestational diabetes mellitus in women with polycystic ovary syndrome: A meta-analysis. Exp Clin Endocrinol Diabetes. 2020;128(3):199-205. https://doi.org/10.1055/a-0603-3394.
  48. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: Molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. https://doi.org/10.1186/s12933-018-0763-3.
  49. Feigenbaum SL, Crites Y, Hararah MK, et al. Prevalence of cervical insufficiency in polycystic ovarian syndrome. Hum Reprod. 2012;27(9):2837-2842. https://doi.org/10.1093/humrep/des193.
  50. Yamamoto M, Feigenbaum SL, Crites Y, et al. Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome. J Perinatol. 2012;32(10):770-776. https://doi.org/10.1038/jp.2011.194.
  51. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011;335(1):30-41. https://doi.org/10.1016/j.mce. 2010.08.002.
  52. Kajihara T, Tanaka K, Oguro T, et al. Androgens modulate the morphological characteristics of human endometrial stromal cells decidualized in vitro. Reprod Sci. 2014;21(3): 372-380. https://doi.org/10.1177/1933719113497280.
  53. Sun M, Maliqueo M, Benrick A, et al. Maternal androgen excess reduces placental and fetal weights, increases placental steroidogenesis, and leads to long-term health effects in their female offspring. Am J Physiol Endocrinol Metab. 2012;303(11):E1373-E1385. https://doi.org/10.1152/ajpendo.00421.2012.
  54. Sir-Petermann T, Hitchsfeld C, Maliqueo M, et al. Birth weight in offspring of mothers with polycystic ovarian syndrome. Hum Reprod. 2005;20(8):2122-2126. https://doi.org/10.1093/humrep/dei009.

Statistics

Views

Abstract - 41

PDF (Russian) - 9

PDF (简体中文) - 3

PDF (English) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2020 Nikolayenkov I.P., Kuzminykh T.U., Tarasova M.A., Seryogina D.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies